Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardian Pharmacy Services, Inc. (NYSE: GRDN), a long-term care pharmacy services company based in Atlanta, Georgia. Through these filings, investors can review how Guardian reports its financial condition, results of operations, and other material events.
Guardian’s recent SEC activity includes multiple Current Reports on Form 8-K. These filings have covered topics such as quarterly financial results, reiteration of financial guidance and preliminary outlook, and the furnishing of investor presentations used at healthcare conferences and in meetings with analysts and other interested parties. Certain 8-Ks also describe lock-up agreements with holders of Class A and Class B common stock following the company’s initial public offering.
The company’s filings confirm that its Class A common stock, par value $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol GRDN. Guardian uses its periodic reports, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q (not reproduced here), to present GAAP financial statements and to discuss risk factors affecting its business.
Guardian also explains in its filings and related press releases how it uses non-GAAP measures such as Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A, and provides reconciliations to the most directly comparable GAAP measures in its full reports. These documents give additional context on how the company evaluates its core operating performance.
On this page, Stock Titan surfaces Guardian’s SEC filings as they are made available on EDGAR and pairs them with AI-generated summaries to help readers understand the key points of each document, from earnings-related 8-Ks to other material disclosures.
On 06/30/2025 The Vanguard Group filed Amendment No. 1 to Schedule 13G covering Guardian Pharmacy Services Inc. (GRDN). Vanguard reports beneficial ownership of 966,806 common shares (CUSIP 40145W101), equal to 4.25 % of the outstanding stock. The investment adviser holds 0 shares with sole voting power and 16,335 shares with shared voting power; it retains 934,250 shares with sole dispositive power and 32,556 shares with shared dispositive power. Vanguard certifies the stake is held in the ordinary course of business with no intent to influence control. Item 5 notes that ownership is now below the 5 % reporting threshold.